Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07093476
PHASE3

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Sponsor: Celltrion

View on ClinicalTrials.gov

Summary

Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately Controlled Type 2 DiabetesMellitus in the Combination Treatment With Metformin and Alogliptin

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

171

Start Date

2025-07-18

Completion Date

2027-04

Last Updated

2025-08-11

Healthy Volunteers

No

Interventions

DRUG

Metformin

tablets, QD, oral administration

DRUG

Alogliptin

tablets, QD, oral administration

DRUG

empagliflozin

tablets, QD, oral administration

Locations (1)

Celltrion

Seoul, South Korea